In our ESMO 2017 Preview series so far we covered our Top 5 immuno-oncology and targeted therapy abstracts to watch out for (the latter has been updated since it first posted so do check it out).

Now it’s time to turn to something completely different.

Castle Manzanares el Real, Madrid

Here we look at hepatocellular carcinoma (HCC), including Blueprint Medicines FGFR4 molecule, BLU–554.

We first covered Blueprint back in February this year with a particular focus on GIST.  Quite a bit has changed since then, so it’s a good time for an update, especially in HCC now that they have data in Madrid.

In the context of the HCC landscape, what’s changing in this niche, what should our expectations be, and how is this market evolving since our last update?

To learn more insights on this important and evolving topic, subscribers can log-in or you can purchase access to BSB Premium Content.

This content is restricted to subscribers

Posted by